echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > HAEMATOLOGICA: Ionophore-mediated osmotic swelling of red blood cells is a potential mechanism for the treatment of sickle cell disease

    HAEMATOLOGICA: Ionophore-mediated osmotic swelling of red blood cells is a potential mechanism for the treatment of sickle cell disease

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sickle cell disease (SCD) is a genetic disorder of the hemoglobin molecule.
    When the hemoglobin molecule is exposed to various environments, the red blood cell hemoglobin polymerizes and twists into a sickle shape
    .


    This deformation allows red blood cells to pass between cells, resulting in damage to downstream tissue nutrition


    Sickle cell disease (SCD) is a genetic disorder of the hemoglobin molecule.


    Monensin plasma carrier can promote the transmembrane transport of red blood cell membrane sodium, increase the permeability of red blood cell membrane sodium, cause the osmotic expansion of red blood cells, and reduce hemoglobin concentration
    .


    Therefore, in a foreign study, the research team treated the blood samples of 13 SCD patients with 10 nM monensin


    In a foreign study, the research team used 10 nM monensin to treat blood samples from 13 patients with SCD


     

    Figure 1 Data collection and analysis: A) Schematic diagram of monensin treatment workflow
    .


    (B) Representative image of raw speed data


    Figure 1 Data collection and analysis: A) Schematic diagram of monensin treatment workflow


    Figure 2: Related parameter analysis
    .


    (A) MCV and MCHC are not correlated (r=-0.


    Figure 2: Related parameter analysis


    Figure 3: The therapeutic effect and variability of monensin
    .


    (AB) The effect of monensin on MCHC and MCV


    Figure 3: The therapeutic effect and variability of monensin


    Figure 4: Linear correlation analysis
    .


    Pearson correlation coefficient analysis is used to determine the strength of the linear relationship
    .
    (A) The change of MCV was significantly positively correlated with the change of MCHC (r=0.
    91, p<0.
    001)
    .
    (B) Speed ​​recovery and MCV change are also positively correlated (r=0.
    87, p<0.
    001)
    .
    (C) The correlation between speed recovery and MCHC change is the strongest (r=0.
    96, p<0.
    01)
    .

    Figure 4: Linear correlation analysis
    .
    Pearson correlation coefficient analysis is used to determine the strength of the linear relationship
    .
    (A) The change of MCV was significantly positively correlated with the change of MCHC (r=0.
    91, p<0.
    001)
    .
    (B) Speed ​​recovery and MCV change are also positively correlated (r=0.
    87, p<0.
    001)
    .
    (C) The correlation between speed recovery and MCHC change is the strongest (r=0.
    96, p<0.
    01)
    .

     

    Although the degree of response of different samples is different, in most blood samples, monensin treatment causes an increase in cell volume and a decrease in hemoglobin concentration
    .
    The monensin-treated samples also showed reduced blood flow damage under hypoxic conditions relative to the untreated control group
    .
    In addition, there is a significant correlation between the improvement of blood flow and the decrease of hemoglobin concentration
    .

    Monensin treatment leads to an increase in cell volume and a decrease in hemoglobin concentration.
    Monensin treatment leads to an increase in cell volume and a decrease in hemoglobin concentration.
    The improvement of blood flow is significantly correlated with the decrease of hemoglobin concentration.
    The improvement of blood flow is related to the decrease of hemoglobin concentration.
    Significant correlation

    Therefore, the results of this study indicate that reducing intracellular HbS concentration through osmotic swelling can improve blood flow under hypoxic conditions
    .
    Although the toxicity of monensin makes it impossible to become a viable clinical treatment, the results still suggest that osmotic swelling as a potential mechanism for SCD treatment should be further studied
    .

    Reducing intracellular HbS concentration by osmotic swelling can improve blood flow under hypoxic conditions.
    Reduced intracellular HbS concentration by osmotic swelling can improve blood flow under hypoxic conditions.
    Although monensin's toxicity makes it impossible to become a viable clinical practice.
    Treatment method.
    Although monensin's toxicity makes it impossible to be a feasible clinical treatment method, osmotic swelling as a potential mechanism of SCD treatment should be further studied
    .
    Osmotic swelling as a potential mechanism of SCD treatment should be further studied
    .

     

    Original source:

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.